Related Experiment Video
Updated: Jul 13, 2026
09:13
Hypoxia Alters miRNAs Levels Involved in Non-Mendelian Inheritance of Autism Spectrum Disorder in Mice
Published on: July 11, 2025
Hypoxia and Alzheimer's disease
Chris Peers1, Hugh A Pearson, John P Boyle
1Faculty of Medicine, University of Leeds, Leeds LS2 9JT, UK. c.s.peers@leeds.ac.uk
Essays in Biochemistry
|August 21, 2007
Summary
Systemic hypoxia, common in cardiorespiratory disorders, increases Alzheimer's disease (AD) risk. Hypoxia promotes amyloid beta peptide formation and disrupts calcium homeostasis, contributing to AD pathogenesis.
Area of Science:
- Neuroscience
- Cardiovascular Medicine
- Pathology
Background:
- Cardiorespiratory disorders frequently cause systemic hypoxia.
- Systemic hypoxia elevates susceptibility to dementia, including Alzheimer's disease (AD).
- The link between hypoxia and AD predisposition was previously unclear.
Purpose of the Study:
- To elucidate the cellular and molecular mechanisms linking systemic hypoxia to Alzheimer's disease (AD).
- To investigate the role of hypoxia-induced cellular changes in AD pathogenesis.
- To explore the potential of mitigating hypoxia's effects to prevent or slow AD onset.
Main Methods:
- Comparative analysis of cellular remodelling in hypoxia and AD.
- Investigation of hypoxia's effect on amyloid beta peptide (Abeta) formation.
- Assessment of hypoxia's impact on mitochondrial ROS generation.
- Examination of hypoxia-induced alterations in voltage-gated calcium channels and intracellular calcium homeostasis.
- Comparison of hypoxia-induced effects with exogenous Abeta application.
Main Results:
- Hypoxia induces cellular remodelling mirroring changes seen in AD.
- Prolonged hypoxia stimulates the formation of amyloid beta peptides (Abetas), key in AD.
- Hypoxia paradoxically increases mitochondrial reactive oxygen species (ROS) production.
- Hypoxia disrupts intracellular calcium homeostasis by altering calcium channels and buffering.
- Hypoxia-induced cellular changes are mimicked by Abeta and depend on its formation.
Conclusions:
- Systemic hypoxia contributes to Alzheimer's disease (AD) pathogenesis through cellular remodelling and Abeta production.
- Hypoxia-induced disruption of calcium homeostasis is a critical factor in AD development.
- Preventing the detrimental effects of hypoxia may offer a strategy for AD prevention or slowing progression.
More Related Videos
12:03Detection of Microregional Hypoxia in Mouse Cerebral Cortex by Two-photon Imaging of Endogenous NADH Fluorescence
Published on: February 21, 2012
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Hypoxia
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...